FOLFIRINOX for 2nd-line Treatment of BTC

NCT03778593 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: Irinotecan
DRUG: Oxaliplatin
DRUG: 5% dextrose water

Sponsor

Dong-A University Hospital